

David R Jayne

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3215078/david-r-jayne-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

52
papers

2,847
citations

24
h-index

53
g-index

65
ext. papers

4,209
ext. citations

5.8
avg, IF

5.17
L-index

#	Paper	IF	Citations
52	Use of Glomerular CD68+ Cells as a Surrogate Marker for Endocapillary Hypercellularity in Lupus Nephritis.. <i>Kidney International Reports</i> , 2022 , 7, 841-847	4.1	0
51	Phase III/IV, Randomized, Fifty-Two-Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2021 ,	9.5	10
50	Efficacy of belimumab in two serologically distinct high disease activity subgroups of patients with systemic lupus erythematosus: post-hoc analysis of data from the phase III programme. <i>Lupus Science and Medicine</i> , 2021 , 8,	4.6	1
49	Avacopan for the Treatment of ANCA-Associated Vasculitis. <i>New England Journal of Medicine</i> , 2021 , 384, 599-609	59.2	109
48	European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	10
47	Pericoronary and periaortic adipose tissue density are associated with inflammatory disease activity in Takayasu arteritis and atherosclerosis. <i>European Heart Journal Open</i> , 2021 , 1, oeab019		1
46	Rheumatological complications of Covid 19. <i>Autoimmunity Reviews</i> , 2021 , 20, 102883	13.6	16
45	Respiratory subtype of relapsing polychondritis frequently presents as difficult asthma: a descriptive study of respiratory involvement in relapsing polychondritis with 13 patients from a single UK centre. <i>ERJ Open Research</i> , 2021 , 7,	3.5	4
44	Medically explained symptoms: a mixed methods study of diagnostic, symptom and support experiences of patients with lupus and related systemic autoimmune diseases. <i>Rheumatology Advances in Practice</i> , 2020 , 4, rkaa006	1.1	11
43	Evaluation of the Safety and Efficacy of Avacopan, a C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Treated Concomitantly With Rituximab or Cyclophosphamide/Azathioprine: Protocol for a Randomized, Double-Blind, Active-Controlled, Phase 3 Trial. <i>JMIR Research Protocols</i> , 2020 , 9, e16664	2	34
42	Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1333-1339	2.4	16
41	Use and reporting of outcome measures in randomized trials for anti-neutrophil cytoplasmic antibody-associated vasculitis: a systematic literature review. <i>Seminars in Arthritis and Rheumatism</i> , 2020 , 50, 1314-1325	5.3	6
40	ANCA-associated vasculitis. <i>Nature Reviews Disease Primers</i> , 2020 , 6, 71	51.1	117
39	Multicriteria decision analysis process to develop new classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 634-640	2.4	35
38	Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. <i>Journal of Allergy and Clinical Immunology</i> , 2019 , 143, 2170-2177	11.5	41
37	Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis. <i>RMD Open</i> , 2019 , 5, e000905	5.9	37
36	Systemic vasculitis and patient-reported outcomes: how the assessment of patient preferences and perspectives could improve outcomes. <i>Patient Related Outcome Measures</i> , 2019 , 10, 37-42	2.9	4

35	Genetic Variants in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Bayesian Approach and Systematic Review. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	12
34	2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1151-1159	2.4	344
33	2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2019 , 71, 1400-1412	9.5	488
32	Evaluation of PR3-ANCA Status After Rituximab for ANCA-Associated Vasculitis. <i>Journal of Clinical Rheumatology</i> , 2019 , 25, 217-223	1.1	15
31	Recommendations for the management of secondary hypogammaglobulinaemia due to B cell targeted therapies in autoimmune rheumatic diseases. <i>Rheumatology</i> , 2019 , 58, 889-896	3.9	12
30	The relapsing polychondritis damage index (RPDAM): Development of a disease-specific damage score for relapsing polychondritis. <i>Joint Bone Spine</i> , 2019 , 86, 363-368	2.9	4
29	Use of Consensus Methodology to Determine Candidate Items for Systemic Lupus Erythematosus Classification Criteria. <i>Journal of Rheumatology</i> , 2019 , 46, 721-726	4.1	29
28	Relapsing polychondritis: a clinical review for rheumatologists. <i>Rheumatology</i> , 2018 , 57, 1525-1532	3.9	34
27	Idiopathic aortitis presenting as pyrexia of unknown origin and delirium. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2018 , 79, 586-587	0.8	
26	Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1064-1069	2.4	61
25	Validation of the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis by disease content experts. <i>RMD Open</i> , 2017 , 3, e000449	5.9	16
24	Comparison of the Phenotype and Outcome of Granulomatosis with Polyangiitis Between UK and Japanese Cohorts. <i>Journal of Rheumatology</i> , 2017 , 44, 216-222	4.1	24
23	[F]-Fluorodeoxyglucose Positron Emission Tomography in the Diagnosis, Treatment Stratification, and Monitoring of Patients with Retroperitoneal Fibrosis: A Prospective Clinical Study. <i>European Urology</i> , 2017 , 71, 926-933	10.2	22
22	Lupus nephritis management guidelines compared. <i>Nephrology Dialysis Transplantation</i> , 2016 , 31, 904-13	4.3	71
21	Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 526-31	2.4	104
20	Current and emerging treatment options in the management of lupus. <i>ImmunoTargets and Therapy</i> , 2016 , 5, 9-20	9	28
19	Con: The use of calcineurin inhibitors in the treatment of lupus nephritis. <i>Nephrology Dialysis Transplantation</i> , 2016 , 31, 1567-71	4.3	12
18	Opponent's comments. <i>Nephrology Dialysis Transplantation</i> , 2016 , 31, 1566-7	4.3	0

17	A historical essay on detection of anti-neutrophil cytoplasmic antibodies. <i>Nephrology Dialysis Transplantation</i> , 2015 , 30 Suppl 1, i8-13	4.3	6
16	Antiphospholipid syndrome. <i>BMJ, The</i> , 2015 , 350, h1426	5.9	4
15	Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials. <i>Rheumatology</i> , 2015 , 54, 471-81	3.9	73
14	Damage in the anca-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 177-84	2.4	143
13	Key issues in the management of patients with systemic lupus erythematosus: latest developments and clinical implications. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2015 , 7, 234-46	3.8	4
12	BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis. <i>Rheumatology</i> , 2014 , 53, 2306-9	3.9	186
11	Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. <i>Arthritis and Rheumatism</i> , 2012 , 64, 542-8		223
10	The Relapsing Polychondritis Disease Activity Index: development of a disease activity score for relapsing polychondritis. <i>Autoimmunity Reviews</i> , 2012 , 12, 204-9	13.6	49
9	Mortality in Wegener's granulomatosis: a bimodal pattern. <i>Rheumatology</i> , 2011 , 50, 697-702	3.9	58
8	Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 1036-43	2.4	253
7	Assessment of damage in vasculitis: expert ratings of damage. <i>Rheumatology</i> , 2009 , 48, 823-7	3.9	29
6	Renal manifestations of the antiphospholipid syndrome. <i>Current Rheumatology Reports</i> , 2009 , 11, 52-60	4.9	13
5	Raised Intracranial Pressure Due to Compression of the Jugular Vein in Wegener's Granulomatosis. <i>Neuro-Ophthalmology</i> , 2008 , 32, 309-311	0.9	
4	Anabolic steroid-induced rhabdomyolysis. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2005 , 66, 362	0.8	7
3	Why do we need a new journal in autoimmunity?. <i>Journal of Autoimmune Diseases</i> , 2004 , 1, 1		1
2	Testing for autoimmunity in humans. <i>Toxicology Letters</i> , 2002 , 127, 93-100	4.4	12
1	Antiendothelial cell antibodies in patients with the antiphospholipid syndrome. <i>Autoimmunity</i> , 1991 , 11, 1-6	3	56